Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 148-153 , September 2009

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

  • Bernhard Resch

      Affiliations

    • Research Unit for Neonatal Infectious Diseases and Epidemiology, Division of Neonatology, Paediatric Department, Medical University of Graz, Austria
    • Corresponding Author InformationCorresponding author. Division of Neonatology, Paediatric Department, Medical University of Graz, Auenbruggerplatz 30, A-8036 Graz, Austria. Tel.: +43 316 385 81134; Fax: +43 316 385 2678.
    • ,
  • Paolo Manzoni

      Affiliations

    • Division of Neonatology and NICU, S. Anna Hospital. ASO O.I.R.M-S.Anna. Torino, Italy
    • ,
  • Marcello Lanari

      Affiliations

    • Paediatrics and Neonatology Unit, Hospital of Imola, Italy

References 

  1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–1928
  2. Glezen WP, Taber LH, Frank AL, Kasel , et al. Risk of primary infection and reinfection with respiratory-syncytial virus. AJDC. 1986;140:543–546
  3. Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Pediatric Health. 2008;2:265–278
  4. The, IMpact-RSV. Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537
  5. Feltes TF, Cabalka AK, Meissner C, et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540
  6. American Academy of Paediatrics: Prevention of respiratory syncytial virus infections: indications for use of of palivizumab and update on the use of RSV-IGIV. Paediatrics 1998; 102:1211–1216.
  7. American Academy of Pediatrics. Revised indications for the use of palivizumab and RSV-IGIV for the prevention of respiratory syncytial virus infection. Pediatrics 2003; 112: 1442–1446 and 1447–1452.
  8. Resch B, Berger A, Urlesberger B, et al. Österreichische Empfehlungen zur RSV Prophylaxe bei Frühgeborenen mit Palivizumab – Update 2003. Monatschr Kinderheilkd. 2004;152:223–224
  9. Raccomandazioni della Societa’ Italiana di Neonatologia per la prevenzione delle malattie da VRS. Aggiornamento 2004 (redatto a cura del Consiglio Direttivo della SIN). Acta Neonatologica & Pediatrica 2004; 18: 19–29.
  10. Simoes EAF. Respiratory syncytial virus infection. Lancet. 1999;354:847–852
  11. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med. 1982;307:397–400
  12. Navas L, Wang EEL, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J Pediatr. 1992;121:348–354
  13. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of pre-operative screening. Pediatr Cardiol. 2000;21:433–438
  14. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:S150–S156
  15. Chevret L, Mbieleu B, Essouri S, et al. Bronchiolitis treated with mechanical ventilation: prognosis factor and outcome in a series of 135 children. Arch Pediatr. 2005;12:385–390
  16. Wolff DS, Fiedelman WM. Respiratory syncytial virus and asthma: is there a link?. J Pediatr Pharm Pract. 1999;4:23–30
  17. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137–141
  18. Korppi M, Piippo-Savolainen E, Korhonen K, et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004;38:155–160
  19. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18:866–869
  20. Panitch HB. Viral respiratory infections in children with technology dependence and neuromuscular disorders. Pediatr Infect Dis J. 2004;23(11 Suppl):S222–S227
  21. Wilkesmann A, Ammann RA, Schildgen O, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26:485–491
  22. Millner ME, de la Monte SM, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndromes. Am J Dis Child. 1985;139:1111–1114
  23. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77–81
  24. Chandwani S, Borkowsky W, Krasinski K, et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr. 1990 Aug;117(2 Pt 1):251–254
  25. King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J. 1993;12:733–739
  26. Schneider S, Borzy MS. Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease. Clin Pediatr (Phila). 1996;35:147–149
  27. Madhi SA, Schoub B, Simmank K, et al. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr. 2000;137:78–84
  28. Piehler JM, Pairolero PC, Gracey DR, et al. Unexplained diaphragmatic paralysis: a harbinger of malignant disease?. J Thorac Cardiovasc Surg. 1982;84:861–864
  29. Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol. 2008;8:229–237
  30. Seddon PC, Khan Y. Respiratory problems in children with neurological impairment. Arch Dis Child. 2003;88:75–78
  31. Kirk CB. Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin?. Arch Dis Child. 2008;93:442–444
  32. Schechter MS. Airway clearance applications in infants and children. Respir Care. 2007;52:1382–1390
  33. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995;333:431–440
  34. Schauer U. Respiratory problems in the immune-compromised host. Pediatr Allergy Immunol. 1996;7:82–85
  35. Deerojanawong J, Chang AB, Eng PA, et al. Pulmonary Diseases in Children with Severe Combined Immune Deficiency and DiGeorge Syndrome. Pediatric Pulmonology. 1997;24:324–330
  36. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2008 as 10.2236/adc.2008.139188 online first.
  37. Lauzon D, Delage G, Brochu P, et al. Pathogens in children with severe combined immune deficiency disease or AIDS. CMAJ. 1986 July 1;135:33–38
  38. Delage G, Brochu P, Robillard L, et al. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. Arch Pathol Lab Med. 1984 Aug;108(8):623–625
  39. Milner ME, de la Monte SM, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am J Dis Child. 1985 Nov;139:1111–1114
  40. Padman R, Bye MR, Schidlow DV, et al. Severe RSV bronchiolitis in an immuno-compromised child. Clin Pediatr (Phila). 1985 Dec;24:719–721
  41. Taylor CE, Osman HK, Turner AJ, et al. Parainfluenza virus and respiratory syncytial virus infection in infants undergoing bone marrow transplantation for severe combined immunodeficiency. Commun Dis Public Health. 1998 Sep;1(3):202–203
  42. Wallace JM. Pulmonary infection in human immunodeficiency disease: viral pulmonary infections. Semin Respir Infect. 1989 Jun;4(2):147–154
  43. Madhi SA, Venter M, Madhi A, et al. Differing manifestations of respiratory syncytial viral-associated severe lower respiratory tract infections in human immunodeficiency virus type-1 infected and uninfected children. Pediatr Infect Dis J. 2001;20:164–170
  44. Wang EEL, Law BJ, Stephens D, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr. 1995;126:212–219
  45. El Saleeby CM, Somes GW, DeVincenzo JP, et al. Risk Factors for Severe RSV Disease in Children with Cancer: The Importance of Lymphopenia and Young Age. Pediatrics. 2008;121:235–243
  46. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis–a prospective birth-cohort study. Pediatrics. 2007;120:e1076–e1081
  47. Blanchard SS, Gerrek MSC, Czinn SJ. Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: Case report and discussion regarding need of routine prophylaxis. Pediatric Transplant. 2006;10:826–829
  48. Boeckh M, Berrey MM, Bowden RA, et al. Phase I evaluation of respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplantation. J Infect Dis. 2001;184:350–354
  49. Manzoni P, Leonessa ML, Farina D, et al. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: The experience of a large Italian neonatal care setting. Pediatr Transplantation. 2007;11:456–457
  50. Speer M, Cohen A, Boron M, et al. Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities and neuromuscular disease (abstract). Pediatr Res. 2004;55:237A–238A
  51. Cohen AH, Bomar R, Cohen LE, et al.. RSV prophylaxis using palivizumab in 86 high-risk children, outside of AAP red book Guidelines. APS/SPR/APA 2001 Convention. April 28, 2001.(Abstr. #2656).
  52. Resch B, Berger A, Bernert G, et al. Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd. 2008;156:381–383
  53. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43:169–174

PII: S1526-0542(09)00043-8

doi: 10.1016/j.prrv.2009.06.003

Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 148-153 , September 2009

Article Tools